Home › Compare › MVAIF vs ABBV
MVAIF yields 2267.57% · ABBV yields 3.06%● Live data
📍 MVAIF pulled ahead of the other in Year 1
Combined, MVAIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MVAIF + ABBV for your $10,000?
Minerva Intelligence Inc., a software development company, provides proprietary AI software and related consulting services. Its principal products include DRIVER uses Machine Learning-based statistical models to automate and accelerate 3D modelling of drilling datasets; Language Extender and Organizer uses controlled vocabularies to automatically index and tag its files, making document management, and searchable, as well as a system for managing a corporation's digital knowledge assets; TARGET, a cognitive AI system that produces explainable exploration targets by mimicking the traditional process of geological data evaluation; SOLACE enables organizations to create and curate standards and design self-improving workflows to align current and future datasets. The company also offers Aristotelian Class Editor, a free software application developed to build taxonomies for use in artificial intelligence applications. In addition, it provides climate85 solutions to enhance the understanding of impacts of climate changes, to adapt and identify opportunities for various industries; and TERRA mining AI platform. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Full MVAIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.